Abstract：Objective: To explore the clinical effect and safety of intraventricular injection with lebezumab in the treatment neonatal vascular eye disease. Methods: 78 patients with choroidal neovascularization admitted to our hospital from February 2016 to December 2017 were randomly divided into control group and study group, 39 cases in each group. The control group was treated with vitrified photodynamic therapy (PDT), and the study group was treated with intravitreal injection of razomab. The clinical efficacy, best corrected visual acuity, macular foveal retinal thickness (CRT), and adverse reactions were compared between the two groups. Results: The effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). There was no difference in the best corrected visual acuity and CRT between the two groups before treatment (P>0.05). The best corrected visual acuity and CRT of the two groups increased in 1 month and decreased in 6 months after treatment, and the change was more obvious in the study group. There were significant differences in the best corrected visual acuity and CRT between the two groups in 1 month and 6 months after treatment (P<0.05). The incidence of adverse reactions in the control group and the study group were 10.26% (4/39) and 12.82% (5/39), respectively. There was no significant difference between the two groups (P > 0.05). Conclusion: Intravitreal injection of razomab in the treatment of choroidal neovascularization has a prominent effect. And it can improve visual acuity, improve retinal edema, worthy of clinical promotion.
杨进寿,张蓉,祁恩. 玻璃体腔注射雷珠单抗治疗新生血管性眼病的临床疗效及安全性分析[J]. 河北医学, 2018, 24(11): 1892-1894.
YANG Jinshou, ZHANG Rong, QI En. Clinical Study and Safety of Intraventricular Injection with Lebezumab in the treatment Neonatal Vascular Eye Disease. HeBei Med, 2018, 24(11): 1892-1894.
2018, Vol. 24 
冀公网安备13080202000677号